Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-initiated phase I/II trial in PLX-PAD cell therapy for the treatment of steroid-refractory chronic Graft-versus-Host-Disease (GvHD)

Trial Profile

An investigator-initiated phase I/II trial in PLX-PAD cell therapy for the treatment of steroid-refractory chronic Graft-versus-Host-Disease (GvHD)

Status: Not stated
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 06 Nov 2017 According to a Pluristem Therapeutics media release, Dr. Ron Ram, Director of the Hematology Blood and Marrow Stem Cell Transplantation Unit for the Tel Aviv Sourasky Medical Center will act as principal investigator. Tel Aviv Sourasky Medical Center will support the study and will be responsible for its design and implementation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top